University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.

Ota, H, Mahmoudi, M, Torguson, R, Satler, LF, Suddath, WO, Pichard, AD and Waksman, R (2015) Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. Cardiovasc Revasc Med, 16 (3). pp. 151-155.

Full text not available from this repository.

Abstract

OBJECTIVE: The aim of this study was to compare the safety and efficacy of the everolimus-eluting stents (EES) with the paclitaxel-eluting stent (PES) and sirolimus-eluting stent (SES) for the treatment of bare-metal in-stent restenosis. BACKGROUND: The optimal treatment for bare-metal in-stent restenosis remains controversial. METHODS: The study cohort comprised 322 consecutive patients (543 lesions) who presented with bare-metal in-stent restenosis to our institution and underwent coronary artery stent implantation with EES (114 patients; 181 lesions), PES (65 patients; 116 lesions) and SES (143 patients; 246 lesions). The analyzed clinical parameters were the 1-year rates of death, Q-wave myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), definite stent thrombosis (ST) and major adverse cardiac events (MACE) defined as the composite of death, MI, or TLR at 1-year. RESULTS: The three groups were well matched for the conventional risk factors except for age and chronic kidney disease. The 1-year analyzed clinical parameters were similar in the three groups: death (EES=3.5%, PES=4.6%, SES=4.2%; p=0.94), MI (EES=3.5%, PES=6.3%, SES=2.1%; p=0.31), TLR (EES=9.8%, PES=9.5%, SES=5.7%; p=0.42), TVR (EES=14.3%, PES=11.1%, SES=11.3%; p=0.74), definite ST (EES=0.9%, PES=3.1%, SES=3.5%; p=0.38) and MACE (EES=14.0%, PES=15.4%, SES=10.5%; p=0.54). Male gender (hazard ratio=0.47; 95% confidence interval=0.25-0.88) and number of treated lesions (hazard ratio=1.47; 95% confidence interval=1.06-2.05) were found to be independent predictors of MACE. CONCLUSION: The results of the present study indicate that EES may provide similar safety and efficacy as first generation DES for the treatment of patients presenting with bare-metal in-stent restenosis.

Item Type: Article
Authors :
NameEmailORCID
Ota, HUNSPECIFIEDUNSPECIFIED
Mahmoudi, Mm.mahmoudi@surrey.ac.ukUNSPECIFIED
Torguson, RUNSPECIFIEDUNSPECIFIED
Satler, LFUNSPECIFIEDUNSPECIFIED
Suddath, WOUNSPECIFIEDUNSPECIFIED
Pichard, ADUNSPECIFIEDUNSPECIFIED
Waksman, RUNSPECIFIEDUNSPECIFIED
Date : April 2015
Identification Number : 10.1016/j.carrev.2015.02.005
Uncontrolled Keywords : Bare-metal in-stent restenosis, Everolimus-eluting stent, Target lesion revascularization, Adult, Aged, Aged, 80 and over, Coronary Artery Disease, Coronary Restenosis, Drug-Eluting Stents, Everolimus, Female, Humans, Male, Middle Aged, Myocardial Infarction, Percutaneous Coronary Intervention, Risk Factors, Sirolimus, Treatment Outcome
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:31
Last Modified : 17 May 2017 10:31
URI: http://epubs.surrey.ac.uk/id/eprint/828144

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800